Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Seismic Therapeutic Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split across 2 distinct art units, indicating that the company's filings are being reviewed by different specialized groups within the patent office. The prosecution is being handled by 2 distinct examiners, ensuring a unique perspective for each of the 2 pending office actions.
DESAI, ANAND U is identified as the busiest examiner, currently overseeing 1 pending office action. Since there are 2 distinct examiners for the 2 pending office actions, the workload is distributed, and no single examiner has a dominant role in the portfolio. For practitioners, this distribution across 2 distinct art units and 2 distinct examiners means that the company must manage two separate prosecution tracks, each with its own examiner and technical group requirements within the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DESAI, ANAND U | 1 | 78.5% | +12.7% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19196457 | IgE PROTEASES AND USES THEREOF | DESAI, ANAND U | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19196457 | IgE PROTEASES AND USES THEREOF | DESAI, ANAND U | — |
| 18048747 | DUAL TARGETED IMMUNE REGULATING COMPOSITIONS | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19196457 | IgE PROTEASES AND USES THEREOF | DESAI, ANAND U | 1655 | §102§103§112 | Non-Final OA | — | Pending | May 01, 2025 |
| 18048747 | DUAL TARGETED IMMUNE REGULATING COMPOSITIONS | MOSELEY II, NELSON B | 1642 | §103DP | Non-Final OA | — | Pending | Oct 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial